



October 19, 2017

Company name: RIBOMIC Inc.  
Representative: Yoshikazu Nakamura, President and CEO  
Stock code: 4591  
Listing: Tokyo Stock Exchange, Mothers Market  
Contact: Emiko Nakamura, Corporate Officer,  
Corporate Planning Department

**Australia Substance Patent Received for RBM004 Anti-NGF Aptamer**

RIBOMIC Inc. received notification from its agent of the approval of its joint Australia substance patent application with Fujimoto Pharmaceutical Corporation for an anti-NGF aptamer. The patent registration number is 2012317323.

This substance patent applies to the aptamer that inhibits the action of nerve growth factor (NGF) activity. This substance was patented in Japan and the U.S.. The approval of this latest substance patent provides strong protection for the intellectual property involving RBM004, a project now under way for the development of a drug to alleviate pain.

Activities involving this anti-NGF aptamer patent process will have no effect on results of operations in the fiscal year ending March 31, 2018.

**Anti-NGF aptamer**

R&D activities are under way with the goal of using an anti-NGF aptamer to create a revolutionary pain alleviation drug that reduces pain by inhibiting activity of nerve growth factor, which is known to transmit pain signal from the periphery to the brain. On April 30, 2014, RIBOMIC signed a licensing agreement with Fujimoto Pharmaceutical Corporation (Head office: Matsubara city, Osaka) that granted this company worldwide rights for the development, manufacture and sale of an anti-NGF aptamer drug. Fujimoto Pharmaceutical is currently working on the development of this drug.